Coronary Artery Disease (CAD) (Ischemic Heart Disease) accounted for a 12.5% share of the global clinical trials within the Cardiovascular therapy area in 2020, registering a decrease of 2.2% when compared with the last ten-year average of 14.7% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Coronary Artery Disease
Industry sponsored trials held a 41.8% share of all the clinical trials for Coronary Artery Disease indication in 2020, registering an increase of 11.9% when compared with the ten-year average of 29.9%. Non-industry sponsored trials accounted for a 58.2% share in 2020, marking a decrease of 11.9% over the ten-year average of 70.1%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Coronary Artery Disease trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Coronary Artery Disease trials, accounting for a 56.3% share in 2020, when compared with the five-year average of 66.2% and ten-year average of 55.1%.
Europe was at the second position with a 39.1% share in 2020, over the five-year average of 33.8% and ten-year average of 40.0%, followed by North America with a 13.8% share in 2020, as against five-year and ten-year averages of 16.3% and 24.2% respectively.
South and Central America stood fourth with a 1.1% share in 2020, compared with the five-year average of 8.0% and ten-year average of 8.3%, followed by Middle East and Africa with a 1.1% share in 2020, over five-year and ten-year averages of 6.2% and 8.4% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Coronary Artery Disease trials, accounting for a 40.2% share in 2020, as against the five-year average of 35.5% and ten-year average of 23.9%.
Russia held a 24.1% share in 2020, over the five-year average of 11.3% and ten-year average of 15.7%, followed by the US with a 12.6% share in 2020, compared with the five-year and ten-year averages of 15.8% and 22.8% respectively.
Italy held a 6.9% share in 2020, as against the five-year average of 6.5% and ten-year average of 8.3%.
The UK held a 5.7% share in 2020, over the five-year and ten-year averages of 8.8% and 9.7% respectively.
Top regions of non-industry sponsored Coronary Artery Disease trials
Asia-Pacific was the top region for non-industry sponsored Coronary Artery Disease trials, accounting for a 62.6% share in 2020 when compared with the five-year average of 52.1% and ten-year average of 49.0%.
Europe was at the second position with an 18.3% share in 2020, over the five-year and ten-year averages of 22.2% and 26.0% respectively, followed by Middle East and Africa with an 8.7% share in 2020, as against the five-year average of 15.7% and ten-year average of 12.4%.
North America stood at the fourth position with a 7.0% share in 2020, compared with the five-year average of 11.4% and ten-year average of 13.6%, followed by South and Central America with a 3.5% share in 2020, over the five-year and ten-year averages of 2.3% and 2.4% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Coronary Artery Disease trials, accounting for a 34.8% share in 2020, as against the five-year average of 28.3% and ten-year average of 21.9%.
South Korea held a 12.2% share in 2020, over the five-year average of 7.4% and ten-year average of 8.1%, followed by Iran with a 7.8% share, compared with the five-year and ten-year averages of 13.0% and 9.6% respectively.
Japan held a 5.2% share in 2020, as against the five-year average of 10.0% and ten-year average of 12.8%.
Australia held a 4.3% share in 2020, over the five-year average of 2.2% and ten-year average of 2.3%.
Phase I trials lead industry sponsored clinical trials for Coronary Artery Disease in 2020
Phase I trials held a 61.8% share of industry sponsored clinical trials for Coronary Artery Disease in 2020, over the five-year average of 42.2% and ten-year average of 38.2%.
Phase II trials held a 23.6% share in 2020, as against the five-year average of 20.9% and ten-year average of 20.8%. Phase IV trials held a 13.5% share in 2020, compared with the five-year and ten-year averages of 25.9% and 25.2% respectively.
Phase III trials held a 1.1% share in 2020, over the five-year average of 11.0% and ten-year average of 15.8%.
Phase IV trials lead non-industry sponsored clinical trials for Coronary Artery Disease in 2020
Phase IV trials held a 45.2% share of non-industry sponsored clinical trials for Coronary Artery Disease in 2020, over the five-year average of 46.7% and ten-year average of 45.7%.
Phase II trials held a 23.4% share in 2020, as against the five-year average of 35.0% and ten-year average of 34.1%. Phase III trials held a 22.6% share, compared the five-year and ten-year averages of 14.2% and 15.3% respectively.
Phase I trials held a 8.9% share in 2020, over the five-year average of 4.1% and ten-year average of 4.9%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
